Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
Scientists solve mystery behind why people with defective hemoglobin do not contract malaria

Scientists solve mystery behind why people with defective hemoglobin do not contract malaria

Delayed cord clamping improves irons status in infants

Delayed cord clamping improves irons status in infants

Hemoglobin levels, blood pressure and male gender linked to higher risk of silent strokes in SCA children

Hemoglobin levels, blood pressure and male gender linked to higher risk of silent strokes in SCA children

Researchers identify hepcidin hormone as potential target for atherosclerosis

Researchers identify hepcidin hormone as potential target for atherosclerosis

Incyte receives FDA approval for Jakafi to treat intermediate or high-risk MF

Incyte receives FDA approval for Jakafi to treat intermediate or high-risk MF

Researchers to begin drug development projects for rare and neglected diseases

Researchers to begin drug development projects for rare and neglected diseases

EPO-secreting engineered vessels could reverse anemia

EPO-secreting engineered vessels could reverse anemia

Alnylam announces new data from ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Alnylam announces new data from ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Feraheme as safe and effective as iron sucrose in patients with anemia, CKD

Feraheme as safe and effective as iron sucrose in patients with anemia, CKD

OWH to participate in major kala-azar elimination project

OWH to participate in major kala-azar elimination project

Ligand third quarter total revenues decrease to $5.7 million

Ligand third quarter total revenues decrease to $5.7 million

Study reveals need for defining optimal amount of iron in infant formula

Study reveals need for defining optimal amount of iron in infant formula

Encouraging interim results from daclatasvir Phase IIb study in genotype 1 and 4 HCV patients

Encouraging interim results from daclatasvir Phase IIb study in genotype 1 and 4 HCV patients

New breast and ovarian cancer vaccine in the pipeline: Study

New breast and ovarian cancer vaccine in the pipeline: Study

MILV subsidiary acquires formula to restore proper kidney function

MILV subsidiary acquires formula to restore proper kidney function

Largest-ever implementation study on kala-azar in Asia

Largest-ever implementation study on kala-azar in Asia

UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting

UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting

Tibotec to present results of TMC435 phase 2b study on HCV at AASLD 2011

Tibotec to present results of TMC435 phase 2b study on HCV at AASLD 2011

Vertex announces positive interim data from INCIVEK Phase 2 combination trial on HIV, HCV

Vertex announces positive interim data from INCIVEK Phase 2 combination trial on HIV, HCV

Rheumavax safe and feasible in treating RA

Rheumavax safe and feasible in treating RA

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.